// App-Quantinova.ai

: Challenges in enrolling to metastatic castration-resistant prostate cancer (mCRPC) studies that require androgen receptor splice variant (AR-V) positivity.

Researchers

Presenter

  • Michael Thomas Schweizer

Principal Investigators

  • Kathleen Haugk

  • Heather H. Cheng

  • Jessica L Maes

  • Ruth F Dumpit

  • Peter Nelson

  • Robert B. Montgomery

  • Stephen R Plymate

  • Evan Y. Yu

Medical Centers

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

  • University of Washington, Seattle, WA

  • Seattle Cancer Care Alliance, Seattle, WA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • University of Washington, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • niclosamide

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT02532114

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved